National viral hepatitis control program in India: Call for update

被引:3
作者
Pandey, Pragya [1 ]
Roy, Akash [2 ]
Bhadoria, Ajeet Singh [1 ,3 ]
机构
[1] All India Inst Med Sci AIIMS, Dept Community & Family Med, Rishikesh, Uttarkhand, India
[2] Apollo Multispecial Hosp, Inst Gastrosciences & Liver Transplantat, Dept Hepatol, Kolkata, W Bengal, India
[3] All India Inst Med Sci AIIMS, Coll Block, Dept Community & Family Med, Fifth Floor, Rishikesh 249203, Uttarakhand, India
关键词
NVHCP; Viral Hepatitis; India;
D O I
10.4103/jfmpc.jfmpc_1455_23
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Viral hepatitis is a serious yet manageable and preventable public health menace that infects about 3 million of people and leads to 1.1 million deaths worldwide every year. An acute episode of viral hepatitis usually subsides on its own, however, if not intervened timely, chronic infection puts people at risk of cirrhosis, liver cancer, and eventually death. In 2015, the global community allied to tackle viral hepatitis, as a result of which combating viral hepatitis target was included in the sustainable development goals (SDGs), and the World Health Organisation (WHO) constituted the first-ever global health sector strategy on viral hepatitis for 2016 to 2021 which is also renewed recently. Conforming to the global commitment, India launched the National Viral Hepatitis Control Program in the year 2018 with the aim to eliminate viral hepatitis as a public health threat by the year 2030. In the Subsequent years, WHO and various other international societies have released updated recommendations with respect to vaccination, prevention of mother-to-child transmission, strategies to increase testing uptake including self-testing, newer diagnostics including point of care and reflex testing approaches, simplified treatment algorithms, expanded treatment eligibility criteria, and simplified service delivery models. With the program being in its fifth year of implementation, there is a need to revamp the operational guidelines based on various global evidence-based advancements in order to attain the ambitious elimination goal by 2030.
引用
收藏
页码:1755 / 1758
页数:4
相关论文
共 23 条
[1]   Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [J].
Ghany M.G. ;
Morgan T.R. .
HEPATOLOGY, 2020, 71 (02) :686-721
[2]   Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4 [J].
Abdel Ghaffar, Tawhida Y. ;
El Naghi, Suzan ;
Abdel Gawad, Manal ;
Helmy, Sarah ;
Abdel Ghaffar, Aisha ;
Yousef, Medhat ;
Moafy, Mohamad .
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (02) :263-270
[3]  
[Anonymous], 2017, Considerations for Adoption and Use of Multi-Disease Testing Devices in Integrated Laboratory Networks
[4]  
[Anonymous], 2023, Recommended package of interventions for HIV, viral hepatitis and STI prevention diagnosis, treatment and care for people who inject drugs
[5]  
[Anonymous], 2021, National Program for Surveillance of Viral Hepatitis. Seroprevalence of Hepatitis B and Hepatitis C. factsheet 2021
[6]  
[Anonymous], 2018, Mother Child Protection Card
[7]  
[Anonymous], 2022, Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection
[8]  
[Anonymous], 2021, The recently completed DTIS and recommendations of the Technical Committee also provides appropriate guidance on these issues
[9]  
[Anonymous], 2023, Screening and testing for hepatitis B virus infection: CDC Recommendations-United States
[10]  
[Anonymous], 2020, CDC Recommendations for Hepatitis C Screening Among Adults